Company: TAK
Filing Date: 2025-10-01
Form Type: 6-K
Source: 0001395064-25-000145
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-01
Form: 6-K
Chunk 1
---
 the decision to discontinue its cell therapy efforts. Takeda will seek an external partner to leverage its cell therapy platform technologies and to further advance the company’s research and clinic-ready programs in this field. The company has no current active clinical trials utilizing cell therapy technology.

Takeda will refocus near-term investments into programs that it believes can deliver transformative therapies to patients at increased speed and scale. The company’s preclinical programs utilizing its in-focus modalities, including small molecules, biologics, and antibody-drug conjugates, are advancing novel and highly innovative therapeutic candidates. Takeda’s preclinical research programs will continue to benefit from the novel insights gained from its cell therapy research.

In the second quarter of the fiscal year ending March 31, 2026 (FY2025), Takeda expects to recognize an impairment loss of approximately JPY 58.0 billion, primarily related to intangible assets associated with the gamma delta T-cell therapy platform. The majority of this impact is expected to be absorbed by the JPY 50.0 billion of impairment losses on intangible assets associated with products, including in-process R&D, included in Takeda's full-year consolidated forecast for FY2025 announced on May 8, 2025. Takeda will continue to assess any other related impacts and, to the extent necessary, reflect them in the second quarter financial results and full-year consolidated forecast, which is scheduled to be announced on October 30, 2025.

#### About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Media Contacts:

#### Takeda Media Relations
media_relations@takeda.com

#### Important Notice
For the purposes of this notice, “statement” means this document, any oral presentation, any question and answer session and